Abstract
A characteristic feature of atopic dermatitis is herpes infection, which necessitates application of antiviral therapy. The analysis of the peptide composition of Laennec drug by de novo mass spectrometric sequencing allowed us to identify over 10 peptides, characterized by potential antiviral effect at all stages of the viral life cycle. Laennec’s peptides can inhibit viral activation (inhibition of protein HCFC1), fusion of the viral envelope with the plasma membrane in the step of the host cell virus infection (inhibition of protein CD4), virus replication (inhibition of protein CTBP1), maturing of virion (inhibition of proteins CRM1, VPS4B, TPR, proline isomerase), budding of the viral particles from the cell membrane (inhibition of the NEDD4 protein). Laennek therapy in complex treatment of patients with atopic dermatitis and herpes virus infection can be substantiated by its pharmacologic activities including antiviral effect.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
